Posted by Michael Wonder on 12 Feb 2019
Seattle Genetics achieves $30 million milestone payment for European Commission approval of Adcetris (brentuximab vedotin) in frontline Hodgkin lymphom
11 February 2019 - Seattle Genetics today announced that its collaborator Takeda has received approval from the European Commission to extend the marketing authorisation for ADCETRIS (brentuximab vedotin) to include Adcetris in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma.
The decision follows a positive opinion from the CHMP on 13 December 2018.
As a result, Seattle Genetics will receive a milestone payment from Takeda of $30 million. Adcetris is an antibody-drug conjugate directed to CD30, a defining marker of classical HL that plays a role in tumour growth and survival.
